Latest Heart valve Stories

Multicenter study in 30 children and young adults shows good early outcomes BOSTON, Oct. 26 /PRNewswire-USNewswire/ -- Children born with certain heart defects have impaired blood flow from the right ventricle to the pulmonary artery leading to the lungs, requiring implanted devices (known as right-ventricular outflow tract conduits) to maintain the flow. However, these conduits fail over time, and children typically face multiple open-heart operations during their lives to reopen the...

ATLANTA, Oct. 6 /PRNewswire-FirstCall/ -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug Administration (FDA) for its CryoValve® SG aortic human heart valve. The HUD designation is the first step in obtaining a Humanitarian Device Exemption (HDE) for the CryoValve SG aortic human heart valve, which is processed with...

2-inch incision provides access to repair diseased valveSurgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve. The majority of those procedures are open-heart operations that require a major incision in the chest. Now, after a six-year study, surgeons at the University of Maryland Medical Center in Baltimore conclude that minimally invasive mitral valve repair techniques,...

SAN FRANCISCO, Sept. 24 /PRNewswire/ -- Mardil, Inc. today announced positive interim data from a pilot study investigating the safety and efficacy of its novel cardiac device - BACE (Basal Annuloplasty of the Cardia Externally) -- in treating mitral valve regurgitation. The condition arises when the heart's mitral valve leaks blood backward into the heart, causing a range of severe and debilitating symptoms. The first 11 patients implanted with BACE demonstrated a significant reduction...

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- The mechanical integrity of the MitraClip(R) device for repair of the mitral valve was maintained for up to five years and with complete healing, according to a subset of data from the EVEREST (Endovascular Valve Edge-to-Edge REpair STudy) study presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco. The data also show complete fibrous encapsulation of the MitraClip device with organized, endocardial tissue...

SAN FRANCISCO, Sept. 22 /PRNewswire/ -- Twelve-month data from EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study high-risk registry arm presented today at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco show that high risk patients with functional mitral regurgitation (MR) following valve repair with the MitraClip(R) system showed a reduction in mitral annular dimension, improvement in heart function and a reduction in hospitalization for...

Research presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF), demonstrated an "exceptionally low" rate of complications one year after implantation of transcatheter aortic valve prostheses.The aortic valve study was led by Sabine Bleiziffer, MD, consultant cardiac surgeon, German Heart Center Munich, Munich, Germany, and will be presented as a poster abstract (TCT-111) on...

ATLANTA, Sept. 21 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY) -- Elite cardiovascular surgeons from around the world will travel to suburban Atlanta this week for the two-day Ross Summit to review and discuss current peer-reviewed data relating to the survival advantage of the Ross Procedure and to practice the technical nuances required to perform this heart surgery successfully. To view the multimedia assets associated with this release, please click...

MINNEAPOLIS, Sept. 21 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today announced that Columbia University Medical Center has achieved 100 implants of the ATS 3f(R) Aortic Bioprosthesis. Based on the precept that 'Form Follows Function,' the ATS 3f Aortic Bioprosthesis is a revolutionary next generation stentless pericardial aortic tissue valve that is unlike any other valve. (Logo:...

SANTA CLARA, Calif., Sept. 16 /PRNewswire/ -- Guided Delivery Systems, Inc. ("GDS") announced the first successful percutaneous implantation of the GDS Accucinch(R) System for mitral valve repair. The procedure was performed by Prof. Dr. med. Joachim Schofer of Medizinisches Versorgungszentrum, Hamburg University Cardiovascular Center in Hamburg, Germany. The GDS Accucinch System significantly reduced the patient's mitral regurgitation without requiring open heart surgery. Dr. Schofer...